Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics, Inc. director David Canner received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036.
The options vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, contingent on his continued board service. Following this award, Canner holds 155,000 derivative securities directly.
Inhibikase Therapeutics, Inc. director Arvind Kush received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and were awarded at no cost to the director.
The options vest on the earlier of June 26, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds stock options for 155,000 underlying shares directly.
Inhibikase Therapeutics director Roberto Bellini received a grant of stock options for 155,000 shares of Common Stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036. Following this grant, he holds 155,000 options directly.
The options will vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, as long as he continues to serve as a director through that date. This is a compensation-related award, not an open-market share purchase or sale.
Inhibikase Therapeutics, Inc. director Vincent Aurentz received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.9100 per share and expire on June 26, 2036. They vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, subject to his continued board service.
Inhibikase Therapeutics, Inc. director Amit Munshi reported a compensation-related grant of stock options. He received options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share, with no cash paid for the grant itself.
The options vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, conditioned on his continued service as a director through that date. After this grant, his reported stock option holdings from this award total 155,000 options, which are scheduled to expire on June 26, 2036.
Inhibikase Therapeutics, Inc. held its 2026 annual meeting of stockholders in a virtual format, where all six management proposals were approved. Stockholders backed an amendment to the 2020 Equity Incentive Plan, increasing the shares reserved for issuance by 3,000,000 common shares.
They also approved a Certificate of Amendment to limit the liability of certain officers as permitted by Delaware law, ratified CohnReznick LLP as independent auditor for 2026, and supported executive compensation on an advisory basis. Directors Arvind Kush and Dennis Berman were re‑elected as Class III directors, and investors chose to hold future say‑on‑pay votes annually.
ADAR1 Capital Management files an amendment reporting beneficial ownership stakes in Inhibikase Therapeutics. ADAR1 Capital Management is shown with 13,860,028 shares representing 9.9% of the issuer's common stock. The filing ties these figures to March 31, 2026 and to an outstanding share base of 132,032,636 shares reported in the issuer's Form 10-Q for the quarter ended March 31, 2026.
The cover pages list related parties: ADAR1 Capital Management GP, LLC with 11,832,998 shares (8.5%) and Daniel Schneeberger with 13,860,028 shares (9.9%). The reported holdings include common stock held by funds and shares underlying milestone warrants as described in the footnotes; the filing states ADAR1 acts in management/sub-advisory roles and may be deemed to indirectly beneficially own the referenced positions.
Inhibikase Therapeutics ownership update: Trails Edge Biotechnology Master Fund reports beneficial ownership of 8,057,345 shares of Inhibikase Therapeutics common stock, representing 6.1% of the outstanding shares as of the Event Date March 31, 2026. The filing states the 8,057,345 shares are held directly by Trails Edge Biotechnology and that Trails Edge Capital and Ortav Yehudai may be deemed to beneficially own the same shares due to management and voting discretion. The ownership percentage is calculated using 132,032,636 shares reported as issued and outstanding in the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2025.
Inhibikase Therapeutics ownership update: Commodore Capital LP, Commodore Capital Master LP and affiliated managers report beneficial ownership of 14,054,940 shares of common stock as of March 31, 2026. This amount is composed of 5,397,488 shares of common stock plus warrants to purchase 5,290,799 Tranche 1 and 3,366,653 Tranche 2 warrants. The filers state a 9.9% beneficial ownership limitation applies. The ownership percentage is calculated using 132,032,636 shares outstanding as of March 31, 2026 from the issuer's Form 10-Q.
INHIBIKASE THERAPEUTICS, INC. ownership disclosure: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report shared beneficial ownership equal to 8.9% of Common Stock.
The filing states 12,635,875 shares of shared voting and dispositive power and references 132,032,636 shares outstanding as of May 1, 2026, assuming exercise of Warrants for 10,320,875 shares subject to a 9.99% ownership limitation.